Mechanism of Toxicity in Rotenone Models of Parkinson's Disease
暂无分享,去创建一个
Todd B. Sherer | Jin Ho Kim | Gary W. Miller | Edward F. Chang | P. Katz | M. Merzenich | S. Bao | G. Miller | T. Sherer | T. Yagi | Jonathan D. Davis | K. Gobeske | A. Sakurai | A. Matsuno-Yagi | C. Testa | Ranjita Betarbet | J. Timothy Greenamyre | Claudia M. Testa | R. Betarbet | J. Richardson | Byoung Boo Seo | Jason R. Richardson | Takao Yagi | Akemi Matsuno-Yagi | B. Seo | Jin Ho Kim | J. Greenamyre | Jonathan D Davis | A. Matsuno‐Yagi | Kevin T. Gobeske | G. Miller
[1] H. Forman,et al. Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity , 2000, The Journal of Biological Chemistry.
[2] A. Storch,et al. 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism , 2000, Journal of Neural Transmission.
[3] Y. Yang,et al. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. , 2000, Neuroscience.
[4] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[5] E. Masliah,et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. , 2000, The American journal of pathology.
[6] C. Marín,et al. Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.
[7] C. Moraes,et al. Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology* , 1999, The Journal of Biological Chemistry.
[8] Y. Kagawa,et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.
[9] A. Matsuno-Yagi,et al. Lack of Complex I Activity in Human Cells Carrying a Mutation in MtDNA-encoded ND4 Subunit Is Corrected by theSaccharomyces cerevisiae NADH-Quinone Oxidoreductase (NDI1) Gene* , 2001, The Journal of Biological Chemistry.
[10] G. Cohen,et al. Coupling of Dopamine Oxidation (Monoamine Oxidase Activity) to Glutathione Oxidation Via the Generation of Hydrogen Peroxide in Rat Brain Homogenates , 1981, Journal of neurochemistry.
[11] M. Zigmond,et al. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. , 1996, Advances in Experimental Medicine and Biology.
[12] Jean Féger,et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats , 2003, Journal of neurochemistry.
[13] G. Cohen,et al. Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione. , 1988, The Journal of pharmacology and experimental therapeutics.
[14] Y. Yang,et al. Enhanced vulnerability to oxidative stress by α-synuclein mutations and C-terminal truncation , 2000, Neuroscience.
[15] Joel S Perlmutter,et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.
[16] R. Nisticò,et al. The role of oxidative stress in paraquat-induced neurotoxicity in rats: protection by non peptidyl superoxide dismutase mimetic , 2003, Neuroscience Letters.
[17] E. Masliah,et al. α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .
[18] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[19] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[20] Robert Hill,et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.
[21] A. Blackburn,et al. Parkinson's disease, pesticides, and glutathione transferase polymorphisms , 1998, The Lancet.
[22] M. Beal,et al. Novel Free Radical Spin Traps Protect against Malonate and MPTP Neurotoxicity , 1999, Experimental Neurology.
[23] D. Muller,et al. A simple method for organotypic cultures of nervous tissue , 1991, Journal of Neuroscience Methods.
[24] D. Eidelberg,et al. Book Review Movement Disorders: Neurologic principles and practice Edited by Ray L. Watts and William C. Koller. 779 pp., illustrated. New York, McGraw-Hill, 1997. $125. 0-07-035203-8 , 1997 .
[25] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[26] T. Sherer,et al. Environment, Mitochondria, and Parkinson's Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[27] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[28] Todd B. Sherer,et al. Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.
[29] C. C. Johnson,et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.
[30] C. Fall,et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. , 1997, Biochimica et biophysica acta.
[31] A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. , 2003 .
[32] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[33] Theodore W Randolph,et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. , 2003, Biochemistry.
[34] J. Parks,et al. Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.
[35] R. W. Gracy,et al. Vitamin E prevents oxidation of antiapoptotic proteins in neuronal cells , 2003, Proteomics.
[36] E. Tolosa,et al. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. , 1993, Neurology.
[37] A. Lees,et al. A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.
[38] T. Flotte,et al. Use of the NADH-Quinone Oxidoreductase (NDI1) Gene ofSaccharomyces cerevisiae as a Possible Cure for Complex I Defects in Human Cells* , 2000, The Journal of Biological Chemistry.
[39] A. Schapira,et al. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. , 1999, Biochimica et biophysica acta.
[40] T. Flotte,et al. A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[41] M. Vila,et al. The rotenone model of Parkinson's disease , 2003, Trends in Neurosciences.
[42] K. Hensley,et al. Interaction of α‐Phenyl‐N‐tert‐Butyl Nitrone and Alternative Electron Acceptors with Complex I Indicates a Substrate Reduction Site Upstream from the Rotenone Binding Site , 1998, Journal of Neurochemistry.
[43] A. Murphy,et al. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. , 2002, The Biochemical journal.
[44] S. Shin,et al. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. , 2002, The Journal of biological chemistry.
[45] E. Floor,et al. Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.
[46] J. Tillement,et al. Nicotine protects rat brain mitochondria against experimental injuries , 2003, Neuropharmacology.
[47] C. Marsden,et al. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease , 2005, Journal of Neural Transmission.
[48] M. Farrer,et al. Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human α‐Synuclein , 2000 .
[49] J. Langston,et al. Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat , 2002, Neurobiology of Disease.
[50] M. Farrer,et al. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. , 2000, Journal of neurochemistry.
[51] N. Hattori,et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[52] M. Roghani,et al. Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence 1 1 Published on the World Wide Web 3 January 2001. , 2001, Brain Research.
[53] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[54] W. Schmidt,et al. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats , 2002, Behavioural Brain Research.
[55] P. Jenner,et al. Oxidative mechanisms in nigral cell death in Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.
[56] J C Rothwell,et al. Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.
[57] Todd B. Sherer,et al. An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.
[58] S. Shin,et al. Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors* , 2002, The Journal of Biological Chemistry.